Randomised, Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mcg (2 Actuations of 2.5 Mcg) and 10mcg (2 Actuations of 5mcg)) of BI 1744 CL Inhalation Solution Delivered by the Respimat Inhaler, and One Dose (12mcg) of Foradil Delivered by the Aerolizer Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

Randomised, Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mcg (2 Actuations of 2.5 Mcg) and 10mcg (2 Actuations of 5mcg)) of BI 1744 CL Inhalation Solution Delivered by the Respimat Inhaler, and One Dose (12mcg) of Foradil Delivered by the Aerolizer Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Olodaterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 Results assessing long-term safety profile of olodaterol from NCT00793624 and NCT00796653 trials presented at the 113th International Conference of the American Thoracic Society
    • 11 Sep 2013 Pooled safety analysis results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top